Nxera Pharma Co Ltd
(FRA:JSS)
€
7.1
0 (0%)
Market Cap: 655.04 Mil
Enterprise Value: 777.64 Mil
PE Ratio: 0
PB Ratio: 1.56
GF Score: 65/100 Sosei Group Corporation - Special Call Transcript
Jan 05, 2021 / NTS GMT
Release Date Price:
€13.3
(-2.92%)
Unidentified Company Representative
(foreign language)
Shinichi Tamura
Sosei Group Corporation - Founder, Executive Chairman, Representative Executive Officer, President & CEO
(foreign language)
Chris Cargill
Sosei Group Corporation - Executive Officer, Executive VP & CFO
(foreign language)
Over to you now, Miles. Thank you.
Miles Congreve
Sosei Group Corporation - Chief Scientific Officer
Thanks, Chris. So if we can turn to Slide 8, please. Muscarinic M4 and M1 receptors are well-validated targets for both psychosis and cognition and have been worked on by pharmaceutical companies for over 25 years. More than 20 years ago, Eli Lilly successfully demonstrated the antipsychotic effects of an M4/M1 preferring agonist compound called Xanomeline and achieved human proof-of-concept in 2 double-blind, placebo-controlled trials in schizophrenia and Alzheimer's disease patients. The relevant studies are shown on the right-hand side of this slide.
Despite this
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot